Skip to main content
Year archive

BioInvent International — 2022 filings

All 31 regulatory filings released by BioInvent International (BINV) in 2022, sourced directly from the official regulator.

31 Filings
2022 Period
2022 filings (31)
Filing Released Lang
Nomination Committee appointed for BioInvent International’s Annual General Meeting 2023
AGM Information
2022-12-19 English
Valberedning utsedd inför BioInvent Internationals årsstämma 2023
Board/Management Information
2022-12-19 Swedish
Earnings Release 2022
Earnings Release 9M 2022
2022-10-27 Swedish
Earnings Release 2022
Earnings Release 9M 2022
2022-10-27 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Q2 2022
2022-08-25 Swedish
Investor Presentation 2022
Investor Presentation
2022-08-25 English
Ändring av antalet aktier och röster i BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements
2022-07-29 Swedish
Change in the number of shares and votes in BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements
2022-07-29 English
BioInvent has successfully carried out a directed share issue of approximately SEK 300 million (approximately USD 28.3 million)
Share Issue/Capital Change
2022-07-12 English
BioInvent har framgångsrikt genomfört en riktad nyemission om cirka 300 MSEK (cirka 28,3 MUSD)
Capital/Financing Update
2022-07-12 Swedish
Beslut på BioInvents extra bolagsstämma den 12 juli 2022
AGM Information
2022-07-12 Swedish
Resolutions at the Extraordinary General Meeting in BioInvent on July 12, 2022
AGM Information
2022-07-12 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-06-21 English
Notice to Extraordinary General Meeting in BioInvent International AB
AGM Information
2022-06-16 English
Kallelse till extra bolagsstämma i BioInvent International AB
AGM Information
2022-06-16 Swedish
Natalie Berner, Redmile och Nanna Lüneborg, Forbion, föreslås som nya styrelseledamöter i BioInvent
Board/Management Information
2022-06-16 Swedish
Natalie Berner of Redmile and Nanna Lüneborg of Forbion proposed as new Board members of BioInvent
Board/Management Information
2022-06-16 English
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
Regulatory Filings
2022-06-16 English
Exelixis och BioInvent sluter exklusivt options- och licensavtal för utveckling av nya, antikroppsbaserade immunonkologiska behandlingar
Regulatory Filings
2022-06-16 Swedish
Major Shareholding Notification 2022
Major Shareholding Notification
2022-06-08 English
Beslut på BioInvents årsstämma 2022
AGM Information
2022-04-28 Swedish
Resolutions at BioInvent’s Annual General Meeting 2022
AGM Information
2022-04-28 English
Earnings Release 2022
Earnings Release Q1 2022
2022-04-27 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q1 2022
2022-04-27 English
Annual Report (ESEF) 2021
Annual Report (ESEF) FY 2021
2022-04-07 Swedish
Notice to Annual General Meeting in BioInvent International AB
AGM Information
2022-03-28 English
Kallelse till årsstämma i BioInvent International AB
AGM Information
2022-03-28 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q4 2021
2022-02-23 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q4 2021
2022-02-23 English
BioInvent: The FDA grants Orphan Drug Designation to BI-1206 for the treatment of follicular lymphoma
Regulatory Filings
2022-01-19 English
BioInvent: FDA tilldelar särläkemedelsstatus (Orphan Drug Designation) till BI-1206 för behandling av follikulärt lymfom
Regulatory Filings
2022-01-19 Swedish